InvestorsHub Logo
Followers 58
Posts 10050
Boards Moderated 1
Alias Born 09/21/2016

Re: TTTav66 post# 193473

Tuesday, 05/21/2019 6:56:09 AM

Tuesday, May 21, 2019 6:56:09 AM

Post# of 458747
TTT-Thanks: Brief but entirely adequate new release from Aus. Re:PDD trials

"The clinical trial will seek to measure the neuroprotective effects of Anavex 2-73 and its ability to re-establish the normal function of cells," she said.
Both trial sites are involved in ongoing trials for the same drug as a treatment for Alzheimer's disease, which have shown promising results.
Parkinson's disease patients aged 50 and over who have been diagnosed with dementia will be recruited for the trial. Participants will be randomly assigned to receive Anavex 2-73 or a placebo for 14 weeks.
Researchers will evaluate the impact of the treatment on cognition as well as motor function and sleep quality.
The trial, which is also being conducted at other international sites, has received the support of the Michael J Fox Foundation for Parkinson's Research and Leon Research.



https://www.thesenior.com.au/story/6129556/trial-of-new-drug-to-treat-parkinsons-dementia/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News